- Home
- GNTA vs LUNG Comparison
GNTA vs LUNG Comparison
Compare GNTA & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- LUNG
- Stock Information
- Founded
- GNTA 2014
- LUNG 1995
- Country
- GNTA Italy
- LUNG United States
- Employees
- GNTA N/A
- LUNG N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- LUNG Industrial Specialties
- Sector
- GNTA Health Care
- LUNG Health Care
- Exchange
- GNTA Nasdaq
- LUNG Nasdaq
- Market Cap
- GNTA 62.9M
- LUNG 65.6M
- IPO Year
- GNTA 2021
- LUNG 2020
- Fundamental
- Price
- GNTA $3.05
- LUNG $1.58
- Analyst Decision
- GNTA Strong Buy
- LUNG Buy
- Analyst Count
- GNTA 1
- LUNG 7
- Target Price
- GNTA $25.00
- LUNG $7.66
- AVG Volume (30 Days)
- GNTA 16.2K
- LUNG 507.9K
- Earning Date
- GNTA 01-01-0001
- LUNG 10-29-2025
- Dividend Yield
- GNTA N/A
- LUNG N/A
- EPS Growth
- GNTA N/A
- LUNG N/A
- EPS
- GNTA N/A
- LUNG N/A
- Revenue
- GNTA N/A
- LUNG $90,549,000.00
- Revenue This Year
- GNTA N/A
- LUNG $10.30
- Revenue Next Year
- GNTA N/A
- LUNG $14.72
- P/E Ratio
- GNTA N/A
- LUNG N/A
- Revenue Growth
- GNTA N/A
- LUNG 18.24
- 52 Week Low
- GNTA $2.56
- LUNG $1.47
- 52 Week High
- GNTA $7.28
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- GNTA 38.04
- LUNG 38.66
- Support Level
- GNTA $2.56
- LUNG $1.60
- Resistance Level
- GNTA $3.18
- LUNG $1.76
- Average True Range (ATR)
- GNTA 0.31
- LUNG 0.13
- MACD
- GNTA -0.06
- LUNG 0.02
- Stochastic Oscillator
- GNTA 25.00
- LUNG 2.94
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.